Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Breckenridge Pharmaceutical, a privately held pharmaceutical marketing, R&D company, has entered into an agreement with IDL, a drug development consulting company, to develop and market an abbreviated new drug application for a cancer drug with US branded sales of approximately $600 million.
Subscribe to our email newsletter
Under the terms of this letter of intent (LOI), IDL will develop and manufacture the product which will be marketed and distributed by Breckenridge.
The two companies plan to file an abbreviated new drug application with the FDA in early 2009.